|
|
|
|
|
|
|
Geron Exercises Warrants Raising $15 Million
Tuesday, February 27, 2007
- Stem Cell Business News |
|
|
Menlo Park, Calif.-based Geron Corporation (GERN) said on February 27 that it has exercised warrants to purchase 1,875,000 shares of common stock at $8 a share for gross proceeds of $15 million.
The warrants were issued to institutional investors in connection with the December 2006 financing and would have expired February 28.
The company also issued to the investors new warrants to purchase 1,125,000 shares of common stock at a premium exercisable from June 2007.
The new warrants are substantially the same as the A Warrants issued in the December financing, the company said.
Geron is developing products based on three technologies, including cell-based therapies derived from human embryonic stem cells for applications in multiple chronic diseases.
Contact: http://www.geron.com
Scroll down to see related articles below.
Subscribe
to Stem Cell Lab World, Stem Cell Research News,
Stem Cell Business News for complete access PLUS biweekly
e-mail delivery of a PDF publication you can save on your
computer or print and store in a binder.
Subscribe now!
Click here
to subscribe to a newsletter (including biweekly delivery of PDF
editions PLUS Web site Premium Content) or
click here to
subscribe on a one-month trial basis to all Web site articles,
including archived articles. |
|
Related Articles:
- Geron Posts $9.3 M 2nd Q Loss (Monday, July 31, 2006)
Stem cell research pioneer Geron Corporation on July 31 posted a $9.3 million second quarter loss on revenue of $786,000.
- Geron Works With University To Develop Stem Cell-Derived Cell Types (Thursday, August 10, 2006)
Geron Corporation (GERN) said on August 7 that it will collaborate with the University of Edinburgh (Scotland) on preclinical safety and efficacy studies using three cell types derived from human embryonic stem cells (HESCs).
- ACT, U-Mass. Patent Interference Appeals Dismissed (Wednesday, September 06, 2006)
A federal appeals court has dismissed appeals by a stem cell firm and a university of two earlier patent interference decisions related to cloning technology owned by Geron COrporation.
- Do Democratic Election Gains Portend A Change In Federal Stem Cell Policy? (Wednesday, November 08, 2006)
Some see the big Democratic election gains in the House and Senate as a portent of a change in national stem cell research policy. But is it really?
- Geron To Raise $40 Million In Securities Sale (Thursday, December 14, 2006)
Stem cell research firm Geron Corp. hopes to raise $40 million in a stock sale to institutional investors.
- Geron’s Stem Cell Therapeutic Shows Promise For Repairing Spinal Cord Damage Factors (Wednesday, January 17, 2007)
New studies show that Geron's human embryonic stem cell-based oligodendroglial progenitor therapeutic produces proteins that stimulate the regeneration of neurons damaged during spinal cord injury.
|
|
|
|
|
|
|
|
| |
|
 |
|
|
|
|
 |
